Please use this identifier to cite or link to this item: https://dora.health.qld.gov.au/qldresearchjspui/handle/1/4573
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMazzoni, D.en
dc.contributor.authorWheller, L.en
dc.contributor.authorLevitt, D.en
dc.contributor.authorLobo, Y.en
dc.date.accessioned2022-11-07T23:54:11Z-
dc.date.available2022-11-07T23:54:11Z-
dc.date.issued2022en
dc.identifier.citation, 2022en
dc.identifier.otherRISen
dc.identifier.urihttp://dora.health.qld.gov.au/qldresearchjspui/handle/1/4573-
dc.description.abstractWhile dupilumab has emerged as a novel targeted systemic treatment for severe AD, efficacy and safety-based data in young children are limited. We discuss the case of a 21-month-old child with severe recalcitrant atopic dermatitis successfully treated with dupilumab.L20168802952022-05-23 <br />en
dc.language.isoenen
dc.relation.ispartofPediatric Dermatologyen
dc.titleSevere atopic dermatitis in a 21-month-old boy successfully treated with dupilumaben
dc.typeArticleen
dc.identifier.doi10.1111/pde.14996en
dc.subject.keywordsmaleen
dc.subject.keywordsdupilumaben
dc.subject.keywordsdrug therapyen
dc.subject.keywordsarticleatopic dermatitisen
dc.subject.keywordscase reporten
dc.subject.keywordsinfanten
dc.subject.keywordsclinical articleen
dc.subject.keywordshumanen
dc.relation.urlhttps://www.embase.com/search/results?subaction=viewrecord&id=L2016880295&from=exporthttp://dx.doi.org/10.1111/pde.14996 |en
dc.identifier.risid428en
item.cerifentitytypePublications-
item.openairetypeArticle-
item.fulltextNo Fulltext-
item.languageiso639-1en-
item.grantfulltextnone-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
Appears in Sites:Children's Health Queensland Publications
Show simple item record

Page view(s)

62
checked on Apr 17, 2025

Google ScholarTM

Check

Altmetric


Items in DORA are protected by copyright, with all rights reserved, unless otherwise indicated.